🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study

RecruitingNAAges any - anyAllSecond Xiangya Hospital of Central South Universi…
NCT07097805 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The GLITTER study is comprised of four key components: Team, Technology, Education, and Peer Resources. The aim of the GLITTER Study is to improve the metabolic control rate in patients with type 1 diabetes through a comprehensive management approach.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1\. Patients with type 1 diabetes of all age groups, regardless of disease duration. The diagnosis criteria for type 1 diabetes are met by fulfilling any one point from the first two criteria plus any one point from the third criterion. 1. Clinically diagnosed as Type 1 Diabetes by a specialist physician. 2. Meet any one of the following criteria: A. Age of onset \<15 years B. No obesity at the time of onset C. diabetic ketoacidosis onset D. Maximum random C-peptide \<200 pmol/L 3. Meet any one of the following criteria: A. Initiation and continuation of insulin therapy after diagnosis (excluding pancreas or islet transplantation) B. Positive for islet cell antibodies
💊

What it tests

  • GLITTER comprehensive management
📍

Where

10 sites
Department of Endocrinology and Metabolism, Peking University People's Hospital
Beijing, China
Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University
Beijing, China
Department of Endocrinology and Metabolism, the Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University
Shenzhen, China
Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, China
Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University
Changsha, China
Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical University
Shenyang, China

…and 2 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy